97 related articles for article (PubMed ID: 22846978)
21. Leukemic Phase of Histiocytic Sarcoma of the Digestive System: A Rare Manifestation of a Rare Disease.
Hofstetter L; Aranovich D; Bernstine H; Hayman L; Shahal-Zimra Y; Rabizadeh E; Cohen A; Lahav M; Raanani P; Wolach O
Acta Haematol; 2021; 144(2):229-235. PubMed ID: 33017829
[TBL] [Abstract][Full Text] [Related]
22. Chemotherapeutic alteration of VEGF-/PDGF- and PDGF-Rα/β expression by imatinib in HPV-transformed squamous cell carcinoma compared to HPV-negative HNSCC in vitro.
Schultz JD; Mühlheim K; Erben P; Hofheinz RD; Faber A; Thorn C; Sommer JU; Hörmann K; Sauter A
Oncol Rep; 2011 Nov; 26(5):1099-109. PubMed ID: 21805039
[TBL] [Abstract][Full Text] [Related]
23. A new schedule of CHOP/rituximab plus granulocyte-macrophage colony-stimulating factor is an effective rescue for patients with aggressive lymphoma failing autologous stem cell transplantation.
Olivieri A; Lucesole M; Capelli D; Gini G; Montanari M; Candela M; Troiani E; Scortechini I; Poloni A; Leoni P
Biol Blood Marrow Transplant; 2005 Aug; 11(8):627-36. PubMed ID: 16041313
[TBL] [Abstract][Full Text] [Related]
24. [The effect of the microenvironment of head and neck cancers on tumor progression].
Lukits J
Magy Onkol; 2009 Mar; 53(1):51-9. PubMed ID: 19318327
[TBL] [Abstract][Full Text] [Related]
25. Is there an indication for high-dose chemotherapy in the treatment of bone and soft-tissue sarcoma?
Kasper B; Ho AD; Egerer G
Oncology; 2005; 68(2-3):115-21. PubMed ID: 15886503
[TBL] [Abstract][Full Text] [Related]
26. Molecular targeted therapies for cancer: sorafenib mono-therapy and its combination with other therapies (review).
Ibrahim N; Yu Y; Walsh WR; Yang JL
Oncol Rep; 2012 May; 27(5):1303-11. PubMed ID: 22323095
[TBL] [Abstract][Full Text] [Related]
27. Tumor-specific expression of vascular endothelial growth factor receptor 2 but not vascular endothelial growth factor or human epidermal growth factor receptor 2 is associated with impaired response to adjuvant tamoxifen in premenopausal breast cancer.
Rydén L; Jirström K; Bendahl PO; Fernö M; Nordenskjöld B; Stål O; Thorstenson S; Jönsson PE; Landberg G
J Clin Oncol; 2005 Jul; 23(21):4695-704. PubMed ID: 16034044
[TBL] [Abstract][Full Text] [Related]
28. High tumor levels of vascular endothelial growth factor predict poor response to systemic therapy in advanced breast cancer.
Foekens JA; Peters HA; Grebenchtchikov N; Look MP; Meijer-van Gelder ME; Geurts-Moespot A; van der Kwast TH; Sweep CG; Klijn JG
Cancer Res; 2001 Jul; 61(14):5407-14. PubMed ID: 11454684
[TBL] [Abstract][Full Text] [Related]
29. High-dose melphalan with autologous stem cell transplantation after VAD induction chemotherapy for treatment of amyloid light chain amyloidosis: a single centre prospective phase II study.
Perz JB; Schonland SO; Hundemer M; Kristen AV; Dengler TJ; Zeier M; Linke RP; Ho AD; Goldschmidt H
Br J Haematol; 2004 Dec; 127(5):543-51. PubMed ID: 15566357
[TBL] [Abstract][Full Text] [Related]
30. Clinical relevance of vascular endothelial growth factor and thymidine phosphorylase in patients with node-positive breast cancer treated with either adjuvant chemotherapy or hormone therapy.
Gasparini G; Toi M; Miceli R; Vermeulen PB; Dittadi R; Biganzoli E; Morabito A; Fanelli M; Gatti C; Suzuki H; Tominaga T; Dirix LY; Gion M
Cancer J Sci Am; 1999; 5(2):101-11. PubMed ID: 10198732
[TBL] [Abstract][Full Text] [Related]
31. Pleomorphic large cell hemato-lymphoma (the so-called "malignant histiocytosis"): clinicopathological and immunophenotypic studies in 35 cases.
Srichaikul T; Sonakul D; Meekungwal P; Prayoonwiwat W; Leelasiri A; Pornvicha P; Mongkonsritragoon W; Sriswasdi C
J Med Assoc Thai; 1994 Nov; 77(11):588-98. PubMed ID: 7759967
[TBL] [Abstract][Full Text] [Related]
32. Allogeneic blood stem cell transplantation after a reduced-intensity, preparative regimen: a pilot study in patients with refractory malignancies.
Pedrazzoli P; Da Prada GA; Giorgiani G; Schiavo R; Zambelli A; Giraldi E; Landonio G; Locatelli F; Siena S; Della Cuna GR
Cancer; 2002 May; 94(9):2409-15. PubMed ID: 12015766
[TBL] [Abstract][Full Text] [Related]
33. Targeted therapy of renal cell cancer.
Wysocki PJ; Zolnierek J; Szczylik C; Mackiewicz A
Curr Opin Investig Drugs; 2008 Jun; 9(6):570-5. PubMed ID: 18516756
[TBL] [Abstract][Full Text] [Related]
34. Treatment of peripheral T-cell lymphomas (PTCL) with high-dose chemotherapy and autologous or allogeneic hematopoietic transplantation.
Kahl C; Leithäuser M; Wolff D; Steiner B; Hartung G; Casper J; Freund M
Ann Hematol; 2002 Nov; 81(11):646-50. PubMed ID: 12454703
[TBL] [Abstract][Full Text] [Related]
35. Insulin-like growth factor type 1 receptor (IGF-1R) exclusive nuclear staining: a predictive biomarker for IGF-1R monoclonal antibody (Ab) therapy in sarcomas.
Asmane I; Watkin E; Alberti L; Duc A; Marec-Berard P; Ray-Coquard I; Cassier P; Decouvelaere AV; Ranchère D; Kurtz JE; Bergerat JP; Blay JY
Eur J Cancer; 2012 Nov; 48(16):3027-35. PubMed ID: 22682017
[TBL] [Abstract][Full Text] [Related]
36. Effect of dasatinib in a xenograft mouse model of canine histiocytic sarcoma and in vitro expression status of its potential target EPHA2.
Ito K; Miyamoto R; Tani H; Kurita S; Kobayashi M; Tamura K; Bonkobara M
J Vet Pharmacol Ther; 2018 Feb; 41(1):e45-e48. PubMed ID: 28833247
[TBL] [Abstract][Full Text] [Related]
37. Response to MEK inhibition with trametinib and tyrosine kinase inhibition with imatinib in multifocal histiocytic sarcoma.
Voruz S; Cairoli A; Naveiras O; de Leval L; Missiaglia E; Homicsko K; Michielin O; Blum S
Haematologica; 2018 Jan; 103(1):e39-e41. PubMed ID: 29097496
[No Abstract] [Full Text] [Related]
38. Complete response of a patient with advanced primary splenic histiocytic sarcoma by treatment with chemotherapeutic drugs selected using the collagen gel droplet-embedded culture drug sensitivity test.
Yamamoto Y; Hiasa Y; Hirooka M; Koizumi Y; Takeji S; Tokumoto Y; Tsubouchi E; Ikeda Y; Abe M; Matsuura B; Onji M
Intern Med; 2012; 51(20):2893-7. PubMed ID: 23064563
[TBL] [Abstract][Full Text] [Related]
39. Primary central nervous system histiocytic sarcoma presenting as a postradiation sarcoma: case report and literature review.
Wu W; Tanrivermis Sayit A; Vinters HV; Pope W; Mirsadraei L; Said J
Hum Pathol; 2013 Jun; 44(6):1177-83. PubMed ID: 23356953
[TBL] [Abstract][Full Text] [Related]
40. Apoptosis inhibitor of macrophage (AIM) reduces cell number in canine histiocytic sarcoma cell lines.
Uchida M; Saeki K; Maeda S; Tamahara S; Yonezawa T; Matsuki N
J Vet Med Sci; 2016 Oct; 78(9):1515-1520. PubMed ID: 27246397
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
